Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company developing novel ophthalmic therapeutics. The company commercializes Xdemvy (lotilaner ophthalmic solution), the first FDA-approved treatment for Demodex blepharitis, alongside advancing pipeline candidates for rosacea and Lyme disease. Main revenue drivers derive from commercial sales of Xdemvy to specialty pharmacies, pharmaceutical distributors, and eye care practices. Tarsus Pharmaceuticals serves optometrists, ophthalmologists, eye care clinics, and patients suffering from blepharitis across the United States. The company holds a pioneering market position as the sole provider of a targeted therapeutic for Demodex blepharitis. Headquartered in Irvine, California, Tarsus Pharmaceuticals Inc is listed on the Nasdaq Stock Market.
5 of the funds FundTelligence covers report a position in Tarsus Pharmaceuticals.
- Legal name
- Tarsus Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
Funds holding Tarsus Pharmaceuticals
- Lannebo Global Småbolag — Lannebo · 1.26 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.2 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)